Omeros Skyrockets On $2.1B Novo Nordisk Rare Disease Deal - Novo Nordisk (NYSE:NVO), Omeros (NASDAQ:OMER)

Novo strikes $2.1 billion deal with Omeros for rare disease drug

Today's biotech news includes GSK distancing itself from FDA leucovorin push, Novo's $2.1 billion deal with Omeros, and more.

Novo Buys Omeros Rare-Disease Drug for as Much as $2.1 Billion

Novo Nordisk A/S agreed to pay Omeros Corp. as much as $2.1 billion for rights to an experimental rare-disease drug, as the maker of Ozempic continues to use deal-making to build its pipeline.

Small Biotech Catapults 154% On A $2.1 Billion Novo Deal

Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.

Novo builds pipeline again with $2.1bn Omeros deal

Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders

Omeros Skyrockets On $2.1B Novo Nordisk Rare Disease Deal - Novo Nordisk (NYSE:NVO), Omeros (NASDAQ:OMER)

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro. Novo Nordisk A/S (NYSE:NVO) and Omeros on Wednesday announced an asset purchase and license agreement for the candidate drug za…

Novo wagers up to $2.1B on Omeros’ rare disease drug

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called complement-mediated diseases.